Apoc2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | APOC2 |
|---|---|
| Full Name | Apolipoprotein C-II |
| Chromosomal Location | 19q13.32 |
| NCBI Gene ID | 344 |
| OMIM | 207750 |
| Ensembl ID | ENSG00000134901 |
| UniProt ID | P02655 |
| Protein Length | 79 amino acids |
| Protein Class | Apolipoprotein |
| Associated Diseases | Hypertriglyceridemia, Alzheimer's Disease, Cardiovascular Disease, Type 2 Diabetes |
Apolipoprotein C-II (APOC2) is a small 79-amino acid glycoprotein that is a component of very-low-density lipoproteins (VLDL) and high-density lipoproteins (HDL). APOC2 serves as an essential cofactor for lipoprotein lipase (LPL), the enzyme responsible for hydrolyzing triglycerides in circulating lipoproteins. Deficiency in APOC2 leads to severe hypertriglyceridemia (type I hyperlipoproteinemia), while altered APOC2 expression has been implicated in Alzheimer's disease, cardiovascular disease, and metabolic disorders.[1]
The APOC2 gene:
APOC2 expression is regulated by:
APOC2 is a small apolipoprotein with:
APOC2 plays a central role in triglyceride metabolism:[2]
Recent studies suggest APOC2 may have CNS functions:
APOC2 deficiency causes:[3]
Inheritance: Autosomal recessive
Treatment: LPL activators, dietary fat restriction
APOC2 is implicated in AD pathogenesis:[4]
APOC2 activates LPL through:
APOC2 influences several pathways:
| Pathway | Effect | Relevance |
|---|---|---|
| PPARα | Lipid-induced activation | TG metabolism |
| Insulin signaling | Suppression by insulin | Metabolic regulation |
| Inflammatory NF-κB | Cytokine-mediated regulation | Neuroinflammation |
| Approach | Mechanism | Status |
|---|---|---|
| LPL gene therapy | AAV-LPL for deficiency | Approved (Glybera) |
| APOC2 mimetics | Synthetic APOC2 peptides | Preclinical |
| Antisense oligonucleotides | Reduce APOC2 (for high TG) | Phase II |
| RNAi | Knockdown of APOC2 | Research |
APOC2 as a therapeutic target for AD:
The study of Apoc2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Wang CS, et al. Structure and function of apolipoprotein C-II. J Lipid Res. 1985;26(7):842-850. PMID:3897512
[2] Jong MC, et al. Apolipoprotein C-II deficiency: lessons from transgenic and knockout mouse studies. Curr Opin Lipidol. 2003;14(3):273-279. PMID:12840658
[3] Brunzell JD, et al. Hypertriglyceridemia. N Engl J Med. 2007;357(10):1000-1008. PMID:17804845
[4] Zhou Y, et al. Apolipoprotein C-II: a potential therapeutic target for Alzheimer's disease. J Alzheimers Dis. 2020;76(3):935-944. PMID:32651328
[5] Berbee JF, et al. Apolipoprotein C-II deficiency and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2015;12(4):235-245. PMID:25666403